This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

First Patient Procedure Using The ClearPoint® Neuro Intervention System Performed At Memorial Sloan Kettering Cancer Center In Pediatric Brain Cancer Clinical Trial

MEMPHIS, Tenn. and MUNICH, Aug. 14, 2012 /PRNewswire/ -- MRI Interventions, Inc. (OTCBB: MRIC) and Brainlab AG announced today that the ClearPoint ® Neuro Intervention System is being used in a groundbreaking clinical trial for the treatment of pediatric brain cancer.  Dr. Mark Souweidane (Professor and Vice Chairman, Department of Neurological Surgery; Director of Pediatric Neurosurgery at New York Presbyterian Hospital/Weill Cornell and Memorial Sloan Kettering Cancer Center) and a team at Memorial Sloan Kettering Cancer Center used the ClearPoint System in the delivery of a cancer-fighting agent into the tumor of a pediatric patient while viewing three-dimensional MRI images of the delivery in real-time throughout the procedure. This was the first case in a new clinical trial to administer and study the effects of the radio immunotherapy drug, 124I-8H9, on a diffuse infiltrative pontine glioma (DIPG) tumor, a rare and incurable form of pediatric brain cancer.

Brain tumors of this type are located in the brain stem, which prohibits surgical removal. Radiation is the standard treatment for DIPG, but it does not provide a cure; most patients die within months of diagnosis.  Previous attempts to administer a drug therapy to significantly improve the survival of children afflicted with DIPG have failed.

Dr. Souweidane's group, in collaboration with other investigators, is using the ClearPoint System in the administration of precise amounts of the agent directly into the tumor via MRI-guided convection-enhanced delivery.  The ability to view drug delivery in real-time is crucial in these cases so that the surgeon can confirm that the potent agent has reached the tumor in the correct amount, as well as to avoid hitting healthy critical structures around the tumor. The ClearPoint System allows the surgeon to advance a drug delivery canula in a precise trajectory through the brain and into the tumor, then observe the infusion of the drug in real-time as it slowly "fills" the tumor.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs